OxySure (OXYS) Announces New Milestone: Saves with Model 615 Exceeds 2,500
Frisco, Texas, August 7, 2014 – OxySure Systems, Inc. (OTCQB: OXYS) (“OxySure,” or the “Company”), the medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its “oxygen from powder” technology is excited to announce that the Company’s flagship product, the OxySure Model 615 has achieved a new milestone regarding its successful use. The estimated number of successful saves with the use of Model 615 in medical emergencies has exceeded 2,500. OxySure’s Model 615 is a lifesaving technology and is the world’s leading emergency oxygen device for lay person use.
A ‘save’ is regarded as an incident during which Model 615 was used to assist someone in a medical emergency or other distress situation. Examples of such situations vary widely, and can include serious incidents such as cardiac arrest (in which OxySure is used post-resuscitation), as well as events such as asthma attacks, COPD exacerbations, allergy attacks, heat exhaustion, hypoxia/altitude sickness, migraine attacks, poisoning/overdose, diabetic emergencies, smoke inhalation, seizures, chest pain, fainting, dehydration, near drowning, hyperthermia, injury with trauma, and the treatment of shock. The standard of care in most medical emergencies is for first responders to provide supplemental oxygen to patients typically immediately upon arrival. OxySure’s Model 615 allows lay rescuers to begin sooner, thereby bridging the gap until professional responders arrive on the scene and can provide more advanced care.
“Saving lives and improving medical outcomes in emergencies is a passion for us, and we are delighted by the number of successful saves involving our product in a short period of time,” stated Julian Ross, CEO of OxySure. “We are constantly reminded that these positive outcomes impact lives and families in a very real way, and we look forward to continuing this trend as the installed base of our product increases.”
The Company tracks the number of saves and general usage of Model 615 through various means, including incident reporting and actual feedback from customers, and statistical tracking of repeat orders of replacement cartridges for units that have been used.
About OxySure Systems, Inc.
OxySure Systems, Inc. is a Frisco, Texas-based medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure’s products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other “Immediately Dangerous to Life or Health” (IDLH) environments. www.OxySure.com
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts, including, without limitation, statements that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development, may be deemed to be forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. These statements are subject to risks and uncertainties. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Except as may be required under applicable law, we assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of OxySure Systems, Inc. can be found in the filings of OxySure Systems, Inc. with the U.S. Securities and Exchange Commission.
Investor Relations Contact(s):
Stonegate Securities, Inc.
214-987-4121 / 972-294-6461
investors@oxysure.com
Renmark Financial Communications Inc.
Bettina Filippone: bfilippone@renmarkfinancial.com
John Boidman: jboidman@renmarkfinancial.com
Tel.: (416) 644-2020 or (514) 939-3989
Tags: